This company listing is no longer active
I4AA Stock Overview
A pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Intellipharmaceutics International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.044 |
| 52 Week High | CA$0.082 |
| 52 Week Low | CA$0.025 |
| Beta | 0.40 |
| 1 Month Change | 0% |
| 3 Month Change | -13.59% |
| 1 Year Change | n/a |
| 3 Year Change | -60.96% |
| 5 Year Change | -74.86% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| I4AA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 3.0% |
| 1Y | n/a | -14.7% | 19.3% |
Return vs Industry: Insufficient data to determine how I4AA performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how I4AA performed against the German Market.
Price Volatility
| I4AA volatility | |
|---|---|
| I4AA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I4AA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine I4AA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 11 | Isa Odidi | www.intellipharmaceutics.com |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease.
Intellipharmaceutics International Inc. Fundamentals Summary
| I4AA fundamental statistics | |
|---|---|
| Market cap | €1.79m |
| Earnings (TTM) | -€2.93m |
| Revenue (TTM) | €834.90k |
2.1x
P/S Ratio-0.6x
P/E RatioIs I4AA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I4AA income statement (TTM) | |
|---|---|
| Revenue | US$904.95k |
| Cost of Revenue | US$475.89k |
| Gross Profit | US$429.06k |
| Other Expenses | US$3.60m |
| Earnings | -US$3.17m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 47.41% |
| Net Profit Margin | -350.72% |
| Debt/Equity Ratio | -16.9% |
How did I4AA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/03 02:16 |
| End of Day Share Price | 2024/03/06 00:00 |
| Earnings | 2023/08/31 |
| Annual Earnings | 2022/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intellipharmaceutics International Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Raymond Deacon | Brean Capital |
| Jonathan Aschoff | Brean Capital |